ClinicalTrials.gg
RecruitingNCT05948865Updated Mar 20, 2026

A Phase 1 Study of CPO301 in Adult Patients With Advanced or Metastatic Solid Tumors

A Phase 1 interventional study of CPO301 in Cancer and Cancer, Lung, sponsored by Conjupro Biotherapeutics, Inc.. Recruiting at 14 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-20.

Primary conditionLung NeoplasmsRegistry: NeoplasmsReclassifiedWhy we changed it
Registry
Neoplasms — the first condition term the registry derived for this study.
ClinicalTrials.gg
Lung Neoplasms
Why
  1. The study's listed conditions name Lung Neoplasms, a narrower term within Neoplasms.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Conjupro Biotherapeutics, Inc. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Jun 2023; still recruiting 3 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
132
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 2,461 studies in Lung Neoplasms with a site in United States — 422 open to participants now, 643 under way, 52 of them phase 3. Lung Neoplasms · United States.

Planned enrollment
474th of 1,907
132 · median 48
Started
2023
with 119 others
Phase 1
448 of 2,461
58 open now
Primary completion
2027-05
later than 278 of 637 live
Registered
2,092nd of 2,461
by date

Among the 2,461 studies in Lung Neoplasms with a site in United States, this one is the 474th largest by planned enrollment of the 1,907 interventional ones that give a count, is one of 120 that started in 2023, is one of 448 in phase 1, reaches primary completion later than 278 of the 637 other live ones, and was the 2,092nd registered.

Lung Neoplasms

5,432 studies on the registry are indexed under Lung Neoplasms; 1,348 are open to participants now.

Browse Lung Neoplasms studies →

Open to participants now

422 of the 2,461 studies in Lung Neoplasms with a site in United States are open now. Recruiting first, the newest first:

417 more — sign in →

All 422 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 996 Lung Neoplasms studies recruiting now, 685 (69%) set no upper age limit and 143 (14%) stop at 75 or younger; 45 take children under 18; 143 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 2,461 studies in Lung Neoplasms with a site in United States, or all of them as a file.
02

Study summary

The goal of this clinical trial is to test CPO301, a type of drug called an antibody drug conjugate in adult patients with advanced or metastatic solid tumors.

The main questions it aims to answer are:

  • To assess the safety and tolerability of CPO301 at increasing doses and determine the dose to be used in the second part of the study (Part A)
  • To assess the safety and tolerability of CPO301 at the dose determined to be safe and tolerable in Part A in patients with Non-Small Cell Lung Cancer and potentially other tumor types (Part B)
  • To evaluate how quickly CPO301 is metabolized by the body (pharmacokinetics or PK)
  • To evaluate if antibodies to the study drug develop (immunogenicity)
  • To evaluate preliminary efficacy to the drug
  • To correlate preliminary efficacy with mutations in a biomarker called EGFR

Participants will:

  • Provide written informed consent
  • Undergo screening tests to ensure they are eligible for study treatment
  • Attend all required study visits and receive CPO301 by intravenous injection every 3 weeks until the study doctor determines study treatment should be stopped, based on how well a participant is doing on treatment
  • Be followed for progression every 3 months for up to 2 years
Read the detailed description

This Phase 1 study is a multicenter, dose-escalating, dose-expansion, single agent, 2-part study conducted in patients with advanced or metastatic solid tumors who progressed on ≥1 prior conventional systemic therapy or who were ineligible or intolerant to standard treatment or had no or refused standard treatment.

Dose escalation (Part A) - Dose escalation will be guided by a modified 3+3 design to determine the maximum tolerated dose (MTD) or recommended dose of CPO301 (also known as SYS6010). Determination of dose-limiting toxicity (DLT) will be based on toxicity observed during the DLT observation period (first 21 days [1 cycle]). Dose escalation decisions are made based on the occurrence of DLT. MTD will be determined based on the data of all enrolled participants. To better identify the MTD, one or more dose groups may also be added beyond the planned maximum dose group (if determined to be safe), or between the maximum escalation dose group and the next lower dose group for DLT assessment. Intermediate dose groups and/or adjustment to the dosing frequency may be made

Dose expansion (Part B) - Additional patients will be enrolled at the recommended dose determined in the dose escalation stage. An additional tumor cohort may be added based on data observed in Part A.

03

Conditions studied

  • Cancer
  • Cancer, Lung

Keywords

  • Cancer
  • Non-Small Cell Lung Cancer
  • Solid Tumors
  • Metastatic
  • Advanced
04

In context

Lung Neoplasms Reclassified

5,432 studies on the registry are indexed under Lung Neoplasms; 1,348 are open to participants now.

This study's planned enrollment of 132 is above the median of 60 across 3,665 interventional studies indexed under Lung Neoplasms.

Browse Lung Neoplasms studies →

Lead sponsor

Conjupro Biotherapeutics, Inc. is the lead sponsor of 10 studies on the registry; 3 are open to participants now.

Compared within Lung Neoplasms, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Neoplasms. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Major Inclusion Criteria:

  • Age ≥18 years
  • Patients with confirmed locally advanced or solid tumors who have disease progression, intolerance to prior therapy, are ineligible for available therapies, or refuse standard of care therapy in the metastatic setting.
  • In Part A, patients with solid tumors including but not limited to NSCLC (adenocarcinoma and squamous cell carcinoma), breast cancer, KRAS-wild type colorectal cancer, and head \& neck cancer based on previous result.
  • In Part B, Cohort 1 will exclusively include NSCLC patients with documented EGFR mutations based on previous biopsy result and Cohort 2 will be patients with other cancer(s) suggested to have sensitivity to CPO301 in Part A.
  • At least 1 measurable target lesion present and documented by CT or MRI according to v1.1
  • performance status 0 or 1 at screening
  • >12 weeks

Major Exclusion Criteria:

  • Known, active, or uncontrolled central nervous system (CNS) metastasis or carcinomatous meningitis.
  • Has AEs due to previous anti-tumor treatments not recovered to ≤Grade 1 (except for alopecia; some tolerable chronic toxicities of Grade 2 may be excluded after consultation with the sponsor, as judged by the investigator) according to v5.0.
  • Any serious and/or uncontrolled concurrent illness that may interfere with study participation

Prior therapy

  • Received other drugs or treatments within 4 weeks before the first dose of the investigational drug in the study
  • The time interval between the latest anti-tumor treatment and the first dose of the investigational drug meets the following requirements: Have received anti-tumor treatments such as chemotherapy, radiotherapy, targeted therapy, immunotherapy and other clinical investigational drugs within 4 weeks before the first dose of the investigational drug; have received oral fluoropyrimidines, small molecule targeted drugs within 2 weeks before the first dose of the investigational drug; have received palliative radiotherapy or local therapy within 2 weeks before the first dose of investigational drug.
  • Had major surgery within 4 weeks before the first dose of the investigational drug in the study.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

06

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
132 participants (estimated)

Study arms

  • Experimental
    Part A, Dose Escalation

    Participants receive escalating doses of CPO301 of 0.6 mg/kg, 1.8mg/kg, 3.6 mg/kg, 4.8 mg/kg, 6.4 mg/kg and 8 mg/kg administered by IVI every 3 weeks (Q3W), with 21 days as a treatment cycle.

    Drug: CPO301

  • Experimental
    Part B, Dose Expansion

    Participants receive CPO301 at the recommended phase 2 dose (RP2D) determined in Part A, administered by IVI every 3 weeks (Q3W), with 21 days as a treatment cycle.

    Drug: CPO301

Interventions

  • DrugCPO301

    Administered by intravenous injection

    Also known as: SYS6010

07

What researchers measure

Primary outcomes

  1. To determine the dose to be used in Part B (RP2D)

    To determine the recommended dose of CPO301 to be used as monotherapy in Part B (RP2D)

    Time frame: through study completion, an average of 1 year

  2. Safety and tolerability at RP2D of CPO301 as monotherapy

    as measured by Incidence and severity of AEs per CTCAEv5.0

    Time frame: through study completion, an average of 1 year

Secondary outcomes

  1. Pharmacokinetics (PK)

    The pharmacokinetics (PK) profile of CPO301 will be assessed by measuring the blood concentration of the drug in the plasma at various timepoints and calculation of parameters, such as Peak Plasma Concentration (Cmax)

    Time frame: through study completion, an average of 1 year

  2. Expression of anti-drug antibody (ADA)

    The expression of anti-drug antibodies (ADAs) following administration will be assessed by analysis of serum samples.

    Time frame: through study completion, an average of 1 year

  3. Efficacy assessment

    To document any early indication of clinical efficacy

    Time frame: through study completion, an average of 1 year

Other outcomes

  1. Parts A and B, Exploratory: Correlatives

    To explore the correlation between EGFR status (different mutations, or amplification levels) and efficacy in patients with advanced solid tumors and biomarkers relevant to CPO301 efficacy

    Time frame: through study completion, an average of 1 year

08

Study locations

14 of 14 sites recruiting
  • USC Norris Comprehensive Cancer Center
    Los Angeles, California 90033, United States
    Recruiting
    • Jacob Thomas, MD · Principal investigator
  • Hoag Memorial Hospital Presbyterian
    Newport Beach, California 92658, United States
    Recruiting
    • Carlos R Becerra, MD · Principal investigator
  • UCLA Hematology/Oncology - Santa Monica
    Santa Monica, California 90404, United States
    Recruiting
    • Lee S. Rosen, MD · Principal investigator
  • Sarah Cannon Research Institute (SCRI) at HealthONE
    Denver, Colorado 80218, United States
    Recruiting
    • Gerald Falchook, MD, MS · Principal investigator
  • AdventHealth Cancer Institute
    Celebration, Florida 34747, United States
    Recruiting
    • Guru P. Sonpavde, MD · Principal investigator
  • Florida Cancer Specialists
    Sarasota, Florida 34232, United States
    Recruiting
    • Manish Patel, MD · Principal investigator
  • Dartmouth Hitchcock Medical Center
    Lebanon, New Hampshire 03756, United States
    Recruiting
    • Konstantin Dragnev, MD · Principal investigator
  • Fox Chase Cancer Center
    Philadelphia, Pennsylvania 19111, United States
    Recruiting
    • Anshu Giri, MD · Principal investigator
  • SCRI Oncology Partners
    Nashville, Tennessee 37203, United States
    Recruiting
    • Melissa L Johnson, MD · Principal investigator
  • NEXT Dallas
    Dallas, Texas 75039, United States
    Recruiting
    • Shiraj Sen, MD · Contact
  • NEXT Virginia
    Fairfax, Virginia 22031, United States
    Recruiting
    • Alex Spira, MD · Principal investigator
  • Cross Cancer Institute
    Edmonton, Alberta T6G 1Z2, Canada
    Recruiting
    • Quincy Chu, MD · Principal investigator
  • Juravinski Cancer Centre
    Hamilton, Ontario L8V 5C2, Canada
    Recruiting
    • Rosalyn Juergens, MD, PhD · Principal investigator
  • Princess Margaret Cancer Centre - University Health Network
    Toronto, Ontario M5G 2M9, Canada
    Recruiting
    • Laswson Eng, MD · Principal investigator
09

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2023 (actual). Primary completion is estimated for May 2027, 47 months after the start.

Of 129 industry-sponsored phase 1 interventional studies under Lung Neoplasms, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 57. This study's planned 47 months is above that.

Counting every sponsor, half of 293 studies reached it within 52 months; a quarter within 28 and three quarters within 74.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 22, 2023
First posted
Jul 17, 2023
StartActual
Jun 6, 2023
Primary completionEst.
May 2027
CompletionEst.
Aug 2027
Last update
Mar 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05948865
Lead sponsor
Conjupro Biotherapeutics, Inc.
Responsible party
Sponsor
First posted
Jul 17, 2023
Start date
Jun 6, 2023
Primary completion
May 2027 (estimated)
Completion
Aug 2027 (estimated)
Last update
Mar 20, 2026

Study contacts

Kevin Romanko
Contact
clinicaltrials.gov@cspcus.com
609-686-6502
Audrey Li
Contact
clinicaltrials.gov@cspcus.com
609-356-0210

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Anti-EGFR Antibody-drug Conjugate CPO301

Start the discussion